Galectin Therapeutics Inc.
HealthcareNASDAQ:GALT · NASDAQ Capital Market
+$0.06 today
Vol 0.28M · Avg 0.33M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
24.4%
avg -259.6%
ROIC
-174.3%
avg -390.1%
ROA
-157.9%
avg -153.7%
Analysis
ROE is currently the strongest return metric at 24.4% versus its period average of -259.6%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Joel Lewis | President & CEO | $992,019.00 | — | 56 | $100,000.00 | 0.15% |
Khurram Jamil | Chief Medical Officer | $921,583.00 | — | 50 | $40,057.00 | 0.06% |
Jack W. Callicutt | Chief Financial Officer, Treasurer & Corporate Secretary | $676,019.00 | — | 59 | $100,000.00 | 0.15% |
Jim Wilkins | Head of CMC & Pharmaceutical Development | — | — | — | — | — |
Beth Knowles | Executive Assistant & Officer Manager | — | — | — | — | — |
Robert Tritt | General Counsel | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$40,355.00
Sells
51
$5.56M
Net Sentiment
$5.52M
Net selling
Most Active
CALLICUTT JACK W
13 transactions
1–10 of 56
Analysis
Insiders reported 5 buys worth $40,355.00 and 51 sells worth $5.56M over the last 12 months. That adds up to net selling of $5.52M. CALLICUTT JACK W was the most active insider with 13 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Alpha Tau Medical Ltd.
NASDAQ:DRTS
$889.71M
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$814.99M
Design Therapeutics, Inc.
NASDAQ:DSGN
$685.15M
Aura Biosciences, Inc.
NASDAQ:AURA
$411.52M
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
$304.44M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$300.28M
I-Mab
IMAB
$235.66M
Altimmune, Inc.
NASDAQ:ALT
$230.35M
Quantum-Si incorporated
NASDAQ:QSI
$187.28M
enGene Holdings Inc.
NASDAQ:ENGN
$82.94M
Who manages GALT?
Galectin Therapeutics Inc. (GALT) lists 6 active executives. The top listed executive is Jack W. Callicutt, Chief Financial Officer, Treasurer & Corporate Secretary.
Are GALT insiders buying or selling?
Recent insider activity shows net selling of $2.53M.
Explore More
Continue the stock analysis
Jump to another research area for this company.